236
Participants
Start Date
November 11, 2020
Primary Completion Date
August 1, 2023
Study Completion Date
November 6, 2024
Voxelotor
Participants are randomized 1:1 to receive voxelotor or placebo.
Placebo
Matching placebo.
Gertrude's Children Hospital, Nairobi
King Abdullah International Medical Research Center (KAIMR) Ministry of National Guard - Health, Riyadh
Abu El Rich Hospital, Cairo University Hospital, Cairo
Ain Shams University Hospital-Clinical Research Center (MASRI), Cairo
The Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Alexandria Clinical Research Center, Faculty of Medicine, Alexandria University, Alexandria
Medical University of South Carolina, Charleston
Children's Healthcare of Atlanta: Hughes Spalding, Atlanta
University of Miami, Miami
Azienda Ospedaliera Universita (AOU) Padova, Padua
University of Mississippi Medical Center, Jackson
Kemri/Crdr,Siaya,Kemri Clinical Research Annex, Kisumu
Azienda Ospedaliera Universitaria (AOU) Meyer, Florence
Texas Children's Hospital- Wallace Tower, Houston
"Azienda Ospedaliera Universitaria (A.O.U.) Luigi Vanvitelli", Napoli
Lagos University Teaching Hospital, Lagos
College of Medicine, University of Ibadan, Ibadan
University of Nigeria Teaching Hospital, Enugu
Aminu Kano Teaching Hospital, Kano
Barau Dikko Teaching/ Kaduna State University, Kaduna
Boston Children's Hospital, Boston
Zagazig University Hospital, Alexandria
Sultan Qaboos University Hospital, Muscat
Department of Child Health, University of Ghana Medical School, College of Health Sciences, Accra
Komfo Anokye Teaching Hospital, Kumasi
KEMRI CRDR Clinical Research Annex, Nairobi
Strathmore University Medical Centre, Nairobi
Barts Health NHS Trust, London
Lead Sponsor
Pfizer
INDUSTRY